Paolo Gaibani

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 26

Top Venues

Antibiotics (Basel, Switzerland)

Current issues in molecular biology

Antimicrobial agents and chemotherapy

Microbial drug resistance (Larchmont, N.Y.)

University of Bologna (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

University of Bologna

Italy

PHD :: U.O. Microbiology

Publications

Stefano Amadesi, Marta Palombo, Federica Bovo, Andrea Liberatore, Elena Vecchi, Monica Cricca, Tiziana Lazzarotto, Simone Ambretti, Paolo Gaibani
Clonal Dissemination of Candida auris Clinical Isolates in Northern Italy, 2021. Microbial drug resistance (Larchmont, N.Y.) (2023)
Federica Bovo, Lazzarotto Tiziana, Simone Ambretti, Paolo Gaibani
Comparison of Broth Microdilution, Disk Diffusion and Strip Test Methods for Cefiderocol Antimicrobial Susceptibility Testing on KPC-Producing Klebsiella pneumoniae . Antibiotics (Basel, Switzerland) 12 (3) (2023)
Antonella Marangoni, Stefano Amadesi, Marielle Ezekielle Djusse, Claudio Foschi, Valeria Gaspari, Lazzarotto Tiziana, Paolo Gaibani
Whole Genome Sequencing of a Chlamydia trachomatis Strain Responsible for a Case of Rectal Lymphogranuloma Venereum in Italy. Current issues in molecular biology 45 (3) (2023)
Antonella Marangoni, Stefano Amadesi, Marielle Ezekielle Djusse, Claudio Foschi, Valeria Gaspari, Lazzarotto Tiziana, Paolo Gaibani
Whole Genome Sequencing of a Chlamydia trachomatis Strain Responsible for a Case of Rectal Lymphogranuloma Venereum in Italy. Current issues in molecular biology 45 (3) (2023)
Marta Palombo, Federica Bovo, Stefano Amadesi, Paolo Gaibani
Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria. Antibiotics (Basel, Switzerland) 12 (5) (2023)
Milo Gatti, Matteo Rinaldi, Cecilia Bonazzetti, Paolo Gaibani, Maddalena Giannella, Pierluigi Viale, Federico Pea
Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections? Antimicrobial agents and chemotherapy (2023)
Federica Bovo, Stefano Amadesi, Marta Palombo, Tiziana Lazzarotto, Simone Ambretti, Paolo Gaibani
Clonal dissemination of Klebsiella pneumoniae resistant to cefiderocol, ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam co-producing KPC and OXA-181 carbapenemase. JAC-antimicrobial resistance 5 (4) (2023)
Federica Bovo, Lazzarotto Tiziana, Simone Ambretti, Paolo Gaibani
Comparison of Broth Microdilution, Disk Diffusion and Strip Test Methods for Cefiderocol Antimicrobial Susceptibility Testing on KPC-Producing Klebsiella pneumoniae . Antibiotics (Basel, Switzerland) 12 (3) (2023)
Paolo Gaibani, Nicole Barp, Marco Massari, Emanuele Alberto Negri, Giada Rossini, Caterina Vocale, Chiara Trenti, Altea Gallerani, Samuele Cantergiani, Federico Romani, Mattia Simion, Cristina Mussini, Tiziana Lazzarotto
Case report of Usutu virus infection in an immunocompromised patient in Italy, 2022. Journal of neurovirology (2023)
Antonella Marangoni, Stefano Amadesi, Marielle Ezekielle Djusse, Claudio Foschi, Valeria Gaspari, Lazzarotto Tiziana, Paolo Gaibani
Whole Genome Sequencing of a Chlamydia trachomatis Strain Responsible for a Case of Rectal Lymphogranuloma Venereum in Italy. Current issues in molecular biology 45 (3) (2023)
Paolo Gaibani, Linda Bussini, Stefano Amadesi, Michele Bartoletti, Federica Bovo, Lazzarotto Tiziana, Pierluigi Viale, Simone Ambretti
Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient. Microorganisms 10 (4) (2022)
Paolo Gaibani, Tommaso Giani, Federica Bovo, Donatella Lombardo, Stefano Amadesi, Lazzarotto Tiziana, Marco Coppi, Gian Maria Rossolini, Simone Ambretti
Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing. Antibiotics (Basel, Switzerland) 11 (5) (2022)
Paolo Gaibani, Gabriele Bianco, Stefano Amadesi, Matteo Boattini, Simone Ambretti, Cristina Costa
Increased bla KPC Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate. Antimicrobial agents and chemotherapy 66 (5) (2022)
Milo Gatti, Maddalena Giannella, Matteo Rinaldi, Paolo Gaibani, Pierluigi Viale, Federico Pea
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia. Antibiotics (Basel, Switzerland) 11 (12) (2022)
Paolo Gaibani, Stefano Amadesi, Tiziana Lazzarotto, Simone Ambretti
Complete Genome Sequence of a Multidrug-Resistant Klebsiella pneumoniae Strain Carrying bla OXA181 and bla KPC-125 Carbapenemase. Microbial drug resistance (Larchmont, N.Y.) 28 (9) (2022)
Milo Gatti, Maddalena Giannella, Matteo Rinaldi, Paolo Gaibani, Pierluigi Viale, Federico Pea
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia. Antibiotics (Basel, Switzerland) 11 (12) (2022)
Gabriele Bianco, Paolo Gaibani, Sara Comini, Matteo Boattini, Giuliana Banche, Cristina Costa, Rossana Cavallo, Patrice Nordmann
Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms. Antibiotics (Basel, Switzerland) 11 (12) (2022)
Gabriele Bianco, Paolo Gaibani, Sara Comini, Matteo Boattini, Giuliana Banche, Cristina Costa, Rossana Cavallo, Patrice Nordmann
Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms. Antibiotics (Basel, Switzerland) 11 (12) (2022)
Federica Bovo, Donatella Lombardo, Lazzarotto Tiziana, Simone Ambretti, Paolo Gaibani
Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against KPC -Producing K. pneumoniae Collected from Bacteremic Patients, 2018 to 2020. Antibiotics (Basel, Switzerland) 11 (11) (2022)
Paolo Gaibani, Federica Bovo, Linda Bussini, Tiziana Lazzarotto, Stefano Amadesi, Michele Bartoletti, Pierlugi Viale, Simone Ambretti
Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments. The Journal of antimicrobial chemotherapy 77 (6) (2022)
Milo Gatti, Maddalena Giannella, Matteo Rinaldi, Paolo Gaibani, Pierluigi Viale, Federico Pea
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia. Antibiotics (Basel, Switzerland) 11 (12) (2022)
Milo Gatti, Giulio Virgili, Pier Giorgio Cojutti, Paolo Gaibani, Matteo Conti, Carmelo Sturiale, Federico Pea, Pierluigi Viale
Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime-Avibactam-Based Regimens: A Report of Two Cases. Microorganisms 10 (1) (2022)
Renato Pascale, Zeno Pasquini, Michele Bartoletti, Luca Caiazzo, Giacomo Fornaro, Linda Bussini, Francesca Volpato, Elisa Marchionni, Matteo Rinaldi, Filippo Trapani, Chiara Temperoni, Paolo Gaibani, Simone Ambretti, Francesco Barchiesi, Pierluigi Viale, Maddalena Giannella
Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study. JAC-antimicrobial resistance 3 (4) (2021)
Paolo Gaibani, Donatella Lombardo, Linda Bussini, Federica Bovo, Beatrice Munari, Maddalena Giannella, Michele Bartoletti, Pierluigi Viale, Lazzarotto Tiziana, Simone Ambretti
Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Northern Italy, 2018. Antibiotics (Basel, Switzerland) 10 (5) (2021)
Paolo Gaibani, Elisa Viciani, Michele Bartoletti, Russell E Lewis, Tommaso Tonetti, Donatella Lombardo, Andrea Castagnetti, Federica Bovo, Clara Solera Horna, Marco Ranieri, Pierluigi Viale, Maria Carla Re, Simone Ambretti
The lower respiratory tract microbiome of critically ill patients with COVID-19. Scientific reports 11 (1) (2021)
Paolo Gaibani, Donatella Lombardo, Michele Bartoletti, Simone Ambretti, Caterina Campoli, Maddalena Giannella, Sara Tedeschi, Matteo Conti, Rita Mancini, Maria Paola Landini, Maria Carla Re, Pierluigi Viale, Russell E Lewis
Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 38 (10) (2019)

Paolo Gaibani.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Paolo Gaibani